Chip-S1 Basic Research Kits, Compound Distribution Kits, and MPS Consumables
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The U.S. Food and Drug Administration (FDA), specifically the Center for Drug Evaluation and Research (CDER), Office of Translational Sciences (OTS), Division of Applied Regulatory Science (DARS), is issuing a Request for Information (RFI) for market research. The FDA seeks qualified vendors capable of supplying Chip-S1 Basic Research Kits, Compound Distribution Kits, and other Microphysiological Systems (MPS) consumables. This RFI aims to gather information for planning purposes related to evaluating MPS in drug development. Responses are due June 12, 2026, at 10:00 AM ET.
Scope of Work
The FDA is conducting research to assess the utility of MPS in evaluating bronchopulmonary disposition of anti-infective drugs and drug transfer into human milk. This research supports model qualification, validation, and integration into drug development programs. The RFI specifically seeks information on 17 items, including various Chip-S1 Basic Research Kits, Compound Distribution Kits, and other consumables. Key technical requirements include MPS chips compatible with Emulate's Zoë Culture Module for continuous fluidic flow, inclusion of Steriflip filters and Chip Activation Reagents, sterilization of consumables, functional QC testing, and step-by-step instructions.
Information Requested from Vendors
Vendors are requested to provide comprehensive information covering:
- Company Information: UEI, CAGE code, business size, and available contract vehicles.
- Capability Statement: Experience, quality management systems, certifications, and customer service capabilities.
- Product Information: Ability to supply the listed items, details on alternative products, and datasheets.
- Pricing Information: Estimated unit pricing, volume discounts, and pricing under existing contracts (rough order of magnitude).
- Delivery Capabilities: Lead times, coordination, tracking, and surge capacity.
Contract & Timeline
- Type: Special Notice / Request for Information (RFI)
- Set-Aside: None specified
- Response Due: June 12, 2026, 10:00 AM ET
- Published: May 29, 2026
Submission Instructions
Responses must be submitted electronically to Cynthia.Martin@fda.hhs.gov by the deadline. The subject line should reference the RFI number: "RFI Response – FDA-CDER-OTS-26-RFI-A430 – [Company Name]". Submissions are limited to 10 pages maximum, with PDF or Microsoft Word preferred.
Additional Notes
This RFI is solely for market research and planning purposes and does not constitute a solicitation or commitment to award a contract. The FDA is not obligated to issue a solicitation, and responses will not be reimbursed. Proprietary information should be marked, but confidentiality is not guaranteed.